tiprankstipranks
Relmada Therapeutics (RLMD)
NASDAQ:RLMD
US Market
RLMD
Relmada Therapeutics
RESEARCH TOOLSreports
Want to see RLMD full AI Analyst Report?

Relmada Therapeutics (RLMD) Income Statement

435 Followers

Relmada Therapeutics Income Statement

Last quarter (Q4 2025), Relmada Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q4, Relmada Therapeutics's net income was $-19.87M. See Relmada Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 59.10M$ 83.89M$ 103.70M$ 161.25M$ 125.70M
Depreciation and Amortization
$ 0.00$ 0.00$ 103.70M$ 2.00K$ 1.26K
EBITDA
$ -59.10M$ -83.89M$ 4.91M$ -161.25M$ -125.70M
Operating Income
$ -59.10M$ -83.89M$ -103.70M$ -161.25M$ -125.70M
Other Income/Expenses
$ 1.72M$ 3.91M$ 4.91M$ 4.21M$ -48.32K
Pretax Income
$ -57.39M$ -79.98M$ -98.79M$ -157.04M$ -125.75M
Net Income
$ -57.39M$ -79.98M$ -98.79M$ -157.04M$ -125.75M
Per Share Metrics
Basic EPS
$ -1.45$ -2.65$ -3.28$ -5.30$ -7.16
Diluted EPS
$ -1.45$ -2.65$ -3.28$ -5.30$ -7.16
Weighted Average Shares Outstanding
 39.48M 30.16M 30.10M 29.63M 17.55M
Weighted Average Shares Outstanding (Diluted)
 39.48M 30.16M 30.10M 29.63M 17.55M
Currency in USD

Relmada Therapeutics Earnings and Revenue History